Vorasidenib treatment for adults with WHO Grade 2 IDH‑mutant diffuse glioma
Official title: Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma: A Multicenter, Prospective, Non-interventional Study in Germany
Run by iOMEDICO AG · NCT07240662 · Data updated 2026-11-12
This study will try vorasidenib in adults with IDH1- or IDH2-mutant WHO grade 2 diffuse glioma after surgery to see if it affects quality of life and clinical outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | iOMEDICO AG Industry-sponsored |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Heidelberg) |
| Status | Recruiting |
| Started | December 8, 2025 |
| Main results expected | November 2031 |
| Study ends | January 2032 |
| Registry record updated | January 9, 2026 |
| Trial ID | NCT07240662 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with WHO grade 2 astrocytoma or oligodendroglioma carrying an IDH1 or IDH2 mutation who have had surgery, do not require immediate radiotherapy or chemotherapy, and are starting vorasidenib per the product label are the ideal candidates.
✕Probably not a fit
Patients who need immediate radiotherapy or chemotherapy, who are enrolled in interventional trials, who cannot provide informed consent, or who have contraindications per the vorasidenib label are unlikely to be eligible or benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
VIOLETA is a prospective, observational real-world study collecting data on adults treated with vorasidenib for IDH‑mutant WHO grade 2 diffuse glioma in routine German clinical practice. Eligible patients have undergone surgery, do not need immediate radiotherapy or chemotherapy, and are started on vorasidenib according to the current SmPC; enrollment is allowed up to six weeks after the first dose provided treatment is ongoing. The study focuses on patient-reported outcomes in German, with primary emphasis on quality of life and secondary endpoints including seizure burden, progression-free survival, objective response rate, time to next intervention, and safety. Data will be collected from the treating center (NCT Heidelberg) following local practice patterns to describe how vorasidenib is used and tolerated outside of interventional trials.
Why it matters
Potential benefit: If successful, vorasidenib could help maintain quality of life and delay disease progression in adults with IDH‑mutant WHO grade 2 glioma.
How similar studies have gone: Early-phase clinical studies of vorasidenib have shown promising activity in IDH‑mutant gliomas, but larger and real-world data remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years * WHO grade 2 astrocytoma or oligodendroglioma * Presence of IDH1- or IDH2-mutation * Surgical intervention * No immediate need of radiotherapy or chemotherapy according to the treating physician * Decision for treatment with vorasidenib as per current SmPC * Signed written informed consent\* * Willingness to participate in Patient-Reported Outcome (PRO) assessment in German language * Other criteria according to current SmPC \* Patients are allowed to be enrolled up to 6 weeks after their first intake of vorasidenib but must still be on treatment at the time of enrollment Exclusion Criteria: * Participation in an interventional clinical trial * Patient unable to consent * Other contraindications according to current SmPC.
Where it's running
-
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg
Heidelberg, Germany Recruiting
Study contacts
- Study coordinator: iOMEDICO
- Email: information@iomedico.com
- Phone: +49761152420
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas
This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.
-
Connectome-guided network planning for brain tumor surgery in eloquent areas
This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.
-
AI-powered analysis of brain MRI to help glioma care
Doctors will use AI to study existing MRI scans and patient data from adults with glioma to see if it can help with non-invasive diagnosis and treatment planning.
-
Safusidenib in IDH1-mutant glioma after vorasidenib progression
This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.